Study population
atrial fibrillation, congenital heart disease, diabetes mellitus, ischemic stroke/TIA
DIABETES MELLITUS, CARDIOMYOPATHY, MAY, CONGESTIVE HEART FAILURE, RHEUMATIC VALVULAR HEART DISEASE, ATRIAL FIBRILLATION, HYPERTENSION, CORONARY ARTERY DISEASE
From May 2014 to April 2021, a total of 673 AF patients underwent LAAC were included in our study (retrospectively from 2014 to 2018, prospectively from 2019 to 2021), as shown in Fig. Flow chart of patients who received LAAC devices and completed long-term follow-upThere were exclusion criteria as follows: patients with rheumatic valvular heart disease, mechanical valve replacement, or atrial fibrillation caused by congenital heart disease. The expected lifetime was less than 1 year. Women who are pregnant, lactating or who have a pregnancy plan in the next two years. According to the investigator's judgment, the patients may fail the follow-up.Baseline clinical characteristics like gender, age, hypertension, diabetes mellitus, coronary artery disease, cardiomyopathy, congenital heart disease, congestive heart failure, ischemic stroke/TIA history, CHA2DS2-VASc score, HAS-BLED score and body mass index (BMI) were recorded for every patient.The study was approved by the local ethics board. The retrospective data were collected and analyzed anonymously. Informed consent were obtained for all prospectively enrolled patients before the LAAC procedure.